- Hong Kong-based startup Insilico Medicine develops first wholly A.I.-created drug INS018_055, targeting idiopathic pulmonary fibrosis.
- The discovery process started in 2020 with hopes to overcome challenges with current treatments, after receiving over $400 million in funding.
- Following successful Phase II trials, the company plans to expand the testing population across sites in the U.S. and China.
Menu
